LncARN et régulation de l'expression génétique, p.121 ,
Rare cancers are not so rare: The rare cancer burden in Europe, European Journal of Cancer, vol.47, issue.17, 2011. ,
DOI : 10.1016/j.ejca.2011.08.008
URL : https://hal.archives-ouvertes.fr/hal-00719112
Cancer incidence and mortality in France over the period 1980-?2005. Rev Epidemiol Sante Publique, pp.159-75, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00338335
Childhood Leukemias, New England Journal of Medicine, vol.332, issue.24, pp.1618-1648, 1995. ,
DOI : 10.1056/NEJM199506153322407
Acute myelogenous leukemia, Current Problems in Pediatric and Adolescent Health Care, vol.32, issue.2, pp.50-58, 2002. ,
DOI : 10.1067/mps.2002.121791
Down's syndrome and leukemia: Epidemiology, Genetics, Cytogenetics and Mechanisms of leukomogenesis, Cancer Genetics and Cytogenetics, pp.55-76, 1987. ,
Hematological disorders and leukemia in children with Down syndrome, European Journal of Pediatrics, vol.55, issue.9, pp.1301-1308, 2012. ,
DOI : 10.1016/j.pcl.2007.11.001
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008. ,
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia, Nat Genet, vol.23, issue.2, pp.166-75, 1999. ,
Studies of a familial platelet disorder, Blood, vol.65, issue.3, pp.557-63, 1985. ,
The role of chromosome 21 in hematology and oncology, Genes, Chromosomes and Cancer, vol.55, 2010. ,
DOI : 10.1001/jama.1954.73690210004006b
A role for RUNX1 in hematopoiesis and myeloid leukemia, International Journal of Hematology, vol.3, issue.6, pp.726-760 ,
DOI : 10.4161/cc.3.6.951
Mortality From Lymphohematopoietic Malignancies and Brain Cancer Among Embalmers Exposed to Formaldehyde, JNCI Journal of the National Cancer Institute, vol.1, issue.7, pp.1696-708, 2009. ,
DOI : 10.13031/2013.19461
Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells, Cancer Epidemiology Biomarkers & Prevention, vol.19, issue.1, pp.80-88, 2010. ,
DOI : 10.1158/1055-9965.EPI-09-0762
Overweight and obesity and incidence of leukemia: A meta-analysis of cohort studies, International Journal of Cancer, vol.6, issue.6, pp.1418-1439, 2007. ,
DOI : 10.1038/nri1937
Epidemiology of childhood acute myeloid leukemia. Pediatric Blood & Cancer, pp.728-761, 2013. ,
Chronic Myeloid Leukemia ??? Advances in Biology and New Approaches to Treatment, New England Journal of Medicine, vol.349, issue.15, pp.1451-64, 2003. ,
DOI : 10.1056/NEJMra020777
The blast phase of chronic myeloid leukaemia. Best Practice & Research Clinical Haematology, pp.387-94, 2009. ,
Molecular biology of bcr-abl1-positive chronic myeloid leukemia, Blood, vol.113, issue.8, pp.1619-1649, 2009. ,
DOI : 10.1182/blood-2008-03-144790
4 Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment, Bailli??re's Clinical Haematology, vol.9, issue.1, pp.57-85, 1996. ,
DOI : 10.1016/S0950-3536(96)80037-0
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications, Journal of Clinical Oncology, vol.23, issue.26, pp.6285-95, 2005. ,
DOI : 10.1200/JCO.2005.05.010
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies, haematologica, vol.90, issue.7, pp.949-68, 2005. ,
NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia, Genes, Chromosomes and Cancer, vol.91, issue.4, pp.410-415, 2001. ,
DOI : 10.1073/pnas.91.22.10722
Acute myeloid leukaemia in adults. The Lancet, pp.484-95, 2013. ,
Leucémies aigues de l'adulte. Hematologie ,
Therapy-Related Myeloid Leukemia, Seminars in Oncology, vol.35, issue.4, 2008. ,
DOI : 10.1053/j.seminoncol.2008.04.012
Therapy-?related myeloid leukaemia: A model for leukemogenesis in humans. Chemico-?Biological Interactions, pp.153-154187, 2005. ,
Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies, Journal of Clinical Oncology, vol.21, issue.2, pp.256-65, 2003. ,
DOI : 10.1200/JCO.2003.08.005
Facteurs biologiques du pronostic des leucémies aiguës myéloïdes. Hématologie, pp.59-67, 2004. ,
3 Immunophenotyping of AML and MDS and detection of residual disease, Bailli??re's Clinical Haematology, vol.9, issue.1, pp.35-55, 1996. ,
DOI : 10.1016/S0950-3536(96)80036-9
Immunological classification of acute myeloblastic leukemias: relevance to patient outcome, Leukemia, vol.78, issue.Suppl 1, pp.515-542, 2003. ,
DOI : 10.3109/10428199409052681
Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood, pp.3688-94, 1995. ,
Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia, Neoplasia, vol.16, issue.6, 2014. ,
DOI : 10.1016/j.neo.2014.06.002
Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia, Cancer Genet Cytogenet, 1984. ,
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)], Leukemia, vol.18, issue.1, pp.87-94, 2006. ,
DOI : 10.1038/sj.leu.2403444
Monitoring of minimal residual disease in acute myeloid leukemia. Cancer, pp.4-16, 2008. ,
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease, Leukemia, vol.21, issue.1, 2014. ,
DOI : 10.1016/j.beha.2007.11.013
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series, Blood, vol.102, issue.1, pp.43-52, 2003. ,
DOI : 10.1182/blood-2002-11-3343
21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: Report from an International Workshop, Genes, Chromosomes and Cancer, vol.98, issue.4, pp.379-94, 2002. ,
DOI : 10.1073/pnas.171321298
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents, International Journal of Environmental Research and Public Health, vol.56, issue.12, pp.2075-91, 2012. ,
DOI : 10.3390/cancers3044170
Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia, British Journal of Haematology, vol.94, issue.1, pp.513-542, 2007. ,
DOI : 10.1111/j.1432-1033.1994.00893.x
-positive acute leukemia, Genes, Chromosomes and Cancer, vol.93, issue.12, pp.1114-1136, 2013. ,
DOI : 10.1073/pnas.93.8.3444
A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42, Leukemia, vol.350, issue.2, pp.224-233, 2006. ,
DOI : 10.1056/NEJMoa031046
PRDX4, a member of the peroxiredoxin family, is fused toAML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes, Chromosomes and Cancer, pp.365-70, 2004. ,
A novel gene,FGA7, is fused toRUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia, Genes, Chromosomes and Cancer, vol.88, issue.2, pp.110-118, 2004. ,
DOI : 10.1128/MCB.14.4.2404
Identification of novelRunx1 (AML1) translocation partner genesSH3D19,YTHDf2, andZNF687 in acute myeloid leukemia. Genes, Chromosomes and Cancer, pp.918-950, 2006. ,
analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-?1 Concerted Action: investigation of minimal residual disease in acute leukemia, Leukemia, 1999. ,